|Project Title||Length of Follow-up Time for New Users of Immunosuppressive Drugs|
Wednesday, February 28, 2018
This report contains estimates of the length of follow-up time for new users of immunosuppressive drugs (adalimumab, alemtuzumab, certolizumab, dalfampridine, dimethyl fumarate, etanercept, fingolimod, glatiramer acetate, golimumab, infliximab, interferon beta-1A, interferon beta-1B, mitoxantrone, natalizumab, pegylated intereferon beta-1A, teriflunomide, and ustekinumab) and for patients diagnosed with Crohn's disease, multiple sclerosis, psoriasis, and ulcerative colitis in the Sentinel Distributed Database (SDD). This report was distributed to Data Partners on June 30, 2017.
pegylated interferon beta-1A
|Population / Cohort|
Individuals 18 years of age or older
January 1, 2000 - June 30, 2017
Sentinel Distributed Database (SDD)